Mapping models predicting EQ-5D utilities from KCCQ scores in HFrEF patients achieved internally validated R2 of 48.4-50.5% for the 3L version and 57.7% for the 5L version.
Cohort (n=4,472)
Yes
Mapping KCCQ scores to EQ-5D utilities provides a valid method to generate societal-based utilities for cost-effectiveness analyses in heart failure when direct EQ-5D data are unavailable.
INTRODUCTION: Evaluation of health status benefits, cost-effectiveness, and value of new heart failure therapies is critical for supporting their use. The Kansas City Cardiomyopathy Questionnaire (KCCQ) measures patients' heart failure-specific health status but does not provide utilities needed for cost-effectiveness analyses. We mapped the KCCQ scores to EQ-5D scores so that estimates of societal-based utilities can be generated to support economic analyses. METHODS: Using data from two US cohort studies, we developed models for predicting EQ-5D utilities (3L and 5L versions) from the KCCQ (23- and 12-item versions). In addition to predicting scores directly, we considered predicting the five EQ-5D health state items and deriving utilities from the predicted responses, allowing different countries' health state valuations to be used. Model validation was performed internally via bootstrap and externally using data from two clinical trials. Model performance was assessed using R2, mean prediction error, mean absolute prediction error, and calibration of observed vs. predicted values. RESULTS: The EQ-5D-3L models were developed from 1000 health status assessments in 547 patients with heart failure and reduced ejection fraction (HFrEF), while the EQ-5D-5L model was developed from 3925 patients with HFrEF. For both versions, models predicting individual EQ-5D items performed as well as those predicting utilities directly. The selected models for the 3L had internally validated R2 of 48.4-50.5% and 33.7-45.6% on external validation. The 5L version had validated R2 of 57.7%. CONCLUSION: Mappings from the KCCQ to the EQ-5D can yield the estimates of societal-based utilities to support cost-effectiveness analyses when EQ-5D data are not available.
Thomas et al. (Thu,) conducted a cohort in Heart failure with reduced ejection fraction (HFrEF) (n=4,472). KCCQ to EQ-5D mapping models was evaluated on Model performance assessed using R2, mean prediction error, mean absolute prediction error, and calibration. Mapping models predicting EQ-5D utilities from KCCQ scores in HFrEF patients achieved internally validated R2 of 48.4-50.5% for the 3L version and 57.7% for the 5L version.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: